home > about us > the consortium
By joining Simcyp, you will become part of the Simcyp Consortium. Currently, 70% of the top-40 pharma companies (including all of the top ten) are members of the Simcyp Consortium.
Consortium Members not only gain access to Simcyp’s latest products and consultancy services, but also contribute to the development of the services offered. The Consortium acts as a steering committee to ensure that new Simcyp products and services are relevant to the current and future needs of the members.
Members of the Consortium include:
Actelion, Allergan, AstraZeneca, Daiichi-Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, F.Hoffman-La Roche, Grunenthal GmbH, Lundbeck, Johnson & Johnson Pharmaceutical Research and Development, Merck KGaA Germany, Novartis Pharma, Otsuka, Pfizer, Sanofi, Servier, Takeda, UCB...
Academic associates include: Children's Hospital of Philadelphia, Flinders University of South Australia, Ghent University, Keio University, Leiden University, Seoul National University, Showa Pharmaceutical University, University of Bonn, University at Buffalo, University of Bath, University of Copenhagen, University of Florida, University of Göteborg, University of Hawaii, University of Helsinki, University of Manchester, University of North Carolina, University of Oslo, University of Toronto, University of Uppsala, University of Washington...
Non-profit organisations include: The Hamner Institutes for Health Sciences, Medical Products Agency (MPA), Medicines Evaluation Board (CBG-MEB), Norwegian Medicines Agency, US Environmental Protection Agency (EPA)...
Simcyp is also in continual dialogue with the US Food & Drug Administration (FDA).
Each year, Consortium Members are invited to a meeting at which they provide feedback on their use of the Simcyp Simulator and suggest any features/improvements that they would like adding to the platform.
At each meeting, the Simcyp team presents updates to the databases and Simulator as well as proposals for further development. A list of features is agreed by the Consortium with priorities for the Simcyp team to work on.
Consortium Members receive all new releases of the Simcyp Simulator and access to the Simcyp science team for consultancy on specific issues.
Each year Consortium Members are invited to Focus Group Meetings and webinars which tackle specific problems in the area of in vitro-in vivo extrapolation (IVIVE).
Consortium Members also have access to the member's area of the Simcyp website, with downloads of the latest version of the Simulator and other resources for users.
To join our Consortium and share in its contributions to state-of-the-art drug development, please contact us directly or come to one of our workshops, where you will learn more about the Simcyp Simulator and the services we offer.